Top Story

CVD-REAL 2: SGLT2 inhibitors decrease risk for CV events, death in type 2 diabetes

March 16, 2018
Meeting News

Canagliflozin may have greatest CV benefit in patients with prior HF

March 15, 2018
ORLANDO, Fla. — Among patients with type 2 diabetes, canagliflozin reduces the risk for CV death or hospitalization for HF to a greater degree in patients with
In the Journals

Weight loss drugs show ‘modest’ cardiometabolic benefits

February 27, 2018
Several weight loss medications approved by the FDA have only modest positive effects on cardiometabolic risk profile, according to new research published in…
In the Journals

‘Silent’ diabetes associated with increased event risk after PCI

February 22, 2018
Undetected diabetes and prediabetes were found in about one-third of patients undergoing PCI, and this “silent” diabetes was linked to a significantly…
More Headlines »